Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CRVS

Corvus Pharmaceuticals Inc

Jan 16 • 10:12AM ET

4.72

Dollar change -0.20
Percentage change -3.96	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY GILD REGN VRTX INCY EXEL BLUE IONS BMRN SRPT

| Held by: VTI VXF IBB IWC ITOT AVSC AVUS DFAS BBC BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.93	Insider Own	21.68%	Shs Outstand	62.58M	Perf Week	-16.37%
Market Cap	303.62M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	0.00%	Shs Float	50.33M	Perf Month	-35.98%
Income	-56.83M	PEG	-	EPS next Q	-0.12	Inst Own	28.60%	Short Float	10.79%	Perf Quarter	-29.69%
Sales	0.00M	P/S	-	EPS this Y	-64.58%	Inst Trans	33.42%	Short Ratio	4.63	Perf Half Y	117.74%
Book/sh	0.20	P/B	23.83	EPS next Y	49.55%	ROA	-102.63%	Short Interest	5.43M	Perf Year	127.16%
Cash/sh	0.65	P/C	7.29	EPS next 5Y	-	ROE	-200.48%	52W Range	1.30 - 10.00	Perf YTD	-11.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	19.89%	ROI	-458.00%	52W High	-52.75%	Beta	1.07
Dividend TTM	-	Quick Ratio	0.92	Sales past 5Y	0.00%	Gross Margin	-	52W Low	263.46%	ATR (14)	0.52
Dividend Ex-Date	-	Current Ratio	0.92	EPS Y/Y TTM	-44.85%	Oper. Margin	-	RSI (14)	32.70	Volatility	6.47% 10.68%
Employees	28	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.80
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-392.16%	Payout	-	Rel Volume	0.58	Prev Close	4.92
Sales Surprise	-	EPS Surprise	-445.45%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	1.17M	Price	4.72
SMA20	-11.42%	SMA50	-34.81%	SMA200	7.75%	Trades		Volume	103,622	Change	-3.96%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-02-25	Initiated	H.C. Wainwright	Buy	$11
Aug-18-23	Initiated	Oppenheimer	Outperform	$7
Dec-01-21	Resumed	Jefferies	Buy	$8
May-27-21	Initiated	Cantor Fitzgerald	Overweight	$10
Feb-10-21	Downgrade	Mizuho	Buy → Neutral	$7 → $4
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy	$6
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Guggenheim	Buy
Apr-18-16	Initiated	Credit Suisse	Outperform

Show Previous Ratings

Jan-13-25 07:30AM	Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
Jan-07-25 04:01PM	Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 01:23PM	Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -36.40%
07:30AM	Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
06:45AM	Tessera gets sickle cell funding; Corvus shares slide on eczema data (BioPharma Dive)
04:01PM	Loading…
Dec-17-24 04:01PM	Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 (GlobeNewswire) +7.10%
Dec-04-24 04:05PM	Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity (GlobeNewswire)
Nov-14-24 10:01AM	Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis (GlobeNewswire)
Nov-13-24 02:18AM	Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Nov-12-24 04:13PM	Corvus: Q3 Earnings Snapshot (Associated Press Finance) -9.10%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-09-24 01:40PM	Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Nov-05-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Sep-10-24 08:30AM	Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire) +13.88%
Sep-03-24 04:05PM	Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -9.82%
04:15PM	Loading…
Aug-06-24 04:15PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance) +6.38% +9.67%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 08:30AM	Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (GlobeNewswire) +16.34%
Jul-31-24 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-25-24 08:30AM	Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases (GlobeNewswire) +6.45%
May-31-24 10:00AM	The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now (InvestorPlace)
May-30-24 04:02PM	Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-07-24 05:12PM	Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing (MT Newswires) -12.04% +16.67%
11:07AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:35AM	Q1 2024 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Corvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-06-24 08:58PM	CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024 (InvestorPlace)
04:21PM	Corvus: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
04:02PM	Loading…
May-02-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire) +7.45% +10.98%
08:30AM	Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering (GlobeNewswire)
Apr-17-24 09:35AM	Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks (Zacks) -7.48%
Apr-09-24 04:01PM	Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire) -7.36%
Apr-01-24 09:35AM	Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround (Zacks)
Mar-22-24 12:00PM	Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-21-24 09:48AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 06:32AM	Q4 2023 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -5.61%
Mar-19-24 04:08PM	Corvus: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-13-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024 (GlobeNewswire) -6.00%
Feb-12-24 09:22AM	Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up (Zacks)
08:30AM	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases (GlobeNewswire)
Feb-08-24 04:05PM	Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma (GlobeNewswire) +10.75%
Feb-06-24 04:05PM	Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer (GlobeNewswire)
Jan-23-24 05:00PM	Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell (GlobeNewswire)
Dec-11-23 12:00PM	What Makes Corvus (CRVS) a New Buy Stock (Zacks) -16.15%
Dec-09-23 12:00PM	Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial (GlobeNewswire)
Dec-07-23 09:40AM	Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year? (Zacks)
Nov-21-23 09:40AM	Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year? (Zacks) -6.67%
Nov-08-23 11:56AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:43AM	Q3 2023 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 04:32PM	Corvus: Q3 Earnings Snapshot (Associated Press Finance) +6.76%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 09:15AM	Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition (GlobeNewswire)
Nov-01-23 07:31PM	Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases (GlobeNewswire)
Oct-31-23 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023 (GlobeNewswire)
Sep-06-23 04:05PM	Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA (GlobeNewswire) -21.53%
Aug-30-23 10:01AM	2 Strong Buy Stocks Under $10 That Oppenheimer Sees Surging Over 200% Heres Why They Could Jump (TipRanks) +12.14%
Aug-08-23 04:35PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance) +7.94%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-01-23 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023 (GlobeNewswire)
Jul-06-23 12:59PM	Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818) (GlobeNewswire)
Jun-29-23 07:00AM	Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference (GlobeNewswire) -5.11%
Jun-15-23 07:00AM	Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma (GlobeNewswire) -25.67%
Jun-04-23 08:10AM	Individual investors among Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) largest shareholders, saw gain in holdings value after stock jumped 23% last week (Simply Wall St.)
May-31-23 08:30AM	Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
08:11AM	3 High-Potential Penny Stocks to Buy Now (InvestorPlace)
May-26-23 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.14%
May-17-23 09:00AM	Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma (GlobeNewswire) +36.71%
May-12-23 10:04AM	Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why (Zacks)
May-10-23 04:06PM	Why Are Corvus Pharmaceuticals Trading Higher Today (Benzinga) +32.05% +18.71%
May-08-23 04:11PM	Corvus: Q1 Earnings Snapshot (AP Finance) +8.33%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-24-23 08:38AM	Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) -5.66%
Apr-20-23 09:00AM	Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023 (GlobeNewswire)
Apr-17-23 09:00AM	Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +6.73%
Apr-03-23 08:30AM	CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma (GlobeNewswire) +9.35%
Mar-30-23 06:08AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2022 Earnings Call Transcript (Insider Monkey) +10.02%
Mar-28-23 04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +11.34%
Mar-21-23 04:05PM	Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023 (GlobeNewswire)
Mar-14-23 04:35PM	Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +5.56%
Feb-21-23 02:34PM	Corvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergence (Benzinga)
09:51AM	'Block-and-lock' HIV path targeted by UCSF professor, Peninsula drug company (American City Business Journals)
07:00AM	Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818s (ITK Inhibitor) Potential to Block HIV Latency Reversal (GlobeNewswire)
Feb-02-23 05:41AM	Quite a few insiders invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) last year which is positive news for shareholders (Simply Wall St.)
Dec-12-22 10:00AM	Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition (GlobeNewswire)
Dec-05-22 08:30AM	Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022 (GlobeNewswire)
Nov-14-22 08:30AM	James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology (GlobeNewswire)
Nov-03-22 04:05PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
09:52AM	Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition (GlobeNewswire)
Oct-27-22 04:05PM	Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022 (GlobeNewswire)
Oct-25-22 04:05PM	Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer (GlobeNewswire)
Oct-14-22 09:55AM	Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-04-22 01:15PM	10 Best Stocks to Buy Now According to Jeffrey Diehls Adams Street Partners (Insider Monkey)
Sep-27-22 08:51AM	Corvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancer (Benzinga)
Sep-26-22 04:05PM	Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China (GlobeNewswire)
Sep-06-22 04:05PM	Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +12.04%
Aug-26-22 06:13AM	Great news for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS): Insiders acquired stock in large numbers last year (Simply Wall St.)
Aug-11-22 12:00PM	Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade (Zacks) +12.01%

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones William Benton	See Remarks	May 06 '24	Buy	1.73	20,000	34,624	153,773	May 07 05:06 PM
MILLER RICHARD A MD	President and CEO	May 06 '24	Buy	1.73	577,634	1,000,000	577,634	May 07 05:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRVS

Corvus Pharmaceuticals Inc

Upgrade your FINVIZ experience